Yitoda Biopharmaceuticals

Yitoda Biopharmaceuticals is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative antibody-based therapeutics for oncology. The company focuses on next-generation immune-oncology treatments, including bispecific antibodies and antibody-drug conjugates designed to overcome resistance to current therapies. Their lead programs target well-established pathways such as PD-1/CTLA-4 and VEGF with optimized binding profiles to enhance efficacy and safety. Yitoda aims to address significant unmet medical needs in solid tumors through a robust internal R&D engine and strategic manufacturing capabilities. The company is currently advancing several candidates through Phase 1 and Phase 2 clinical trials in China and internationally.